Louisiana State Employees Retirement System Has $2.48 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Louisiana State Employees Retirement System cut its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 2.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 62,900 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the quarter. Louisiana State Employees Retirement System’s holdings in TG Therapeutics were worth $2,480,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of TGTX. Vermillion Wealth Management Inc. acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at approximately $30,000. NBC Securities Inc. grew its position in TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 823 shares in the last quarter. Golden State Wealth Management LLC increased its stake in TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 433 shares during the last quarter. Quadrant Capital Group LLC lifted its position in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 975 shares in the last quarter. Finally, USA Financial Formulas acquired a new position in shares of TG Therapeutics during the 1st quarter worth about $57,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $38.92 on Tuesday. The firm has a market capitalization of $6.18 billion, a P/E ratio of 162.17 and a beta of 1.91. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. The firm’s fifty day moving average price is $36.05 and its two-hundred day moving average price is $35.32. TG Therapeutics, Inc. has a 1 year low of $16.65 and a 1 year high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. During the same period in the previous year, the company posted ($0.07) earnings per share. The firm’s revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a research report on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.80.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director directly owned 228,816 shares of the company’s stock, valued at $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.64% of the stock is owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.